Alamar, Nightingale Health Team up on UK Biobank Neurodegeneration Protein Study

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 03 Nov, 22:43 UTC

Nightingale Health will run the measurements in its labs using Alamar’s NULISA platform to quantify hundreds of blood proteins in 80,000 UK Biobank samples, seeking early molecular signs of neurodegeneration. The post Alamar, Nightingale Health Team up on UK Biobank Neurodegeneration Protein Study…